Deletion of the transcriptional regulator TFAP4 accelerates c-MYC-driven lymphomagenesis

Many lymphoid malignancies arise from deregulated c-MYC expression in cooperation with additional genetic lesions. While many of these cooperative genetic lesions have been discovered and their functions characterised, DNA sequence data of primary patient samples suggest that many more do exist. However, the nature of their contributions to c-MYC driven lymphomagenesis have not yet been investigated. We identified TFAP4 as a potent suppressor of c-MYC driven lymphoma development in a previous genome-wide CRISPR knockout screen in primary cells in vivo [1]. CRISPR deletion of TFAP4 in Eµ-MYC transgenic haematopoietic stem and progenitor cells (HSPCs) and transplantation of these manipulated HSPCs into lethally irradiated animals significantly accelerated c-MYC-driven lymphoma development. Interestingly, TFAP4 deficient Eµ-MYC lymphomas all arose at the pre-B cell stage of B cell development. This observation prompted us to characterise the transcriptional profile of pre-B cells from pre-leukaemic mice transplanted with Eµ-MYC/Cas9 HSPCs that had been transduced with sgRNAs targeting TFAP4. This analysis revealed that TFAP4 deletion reduced expression of several master regulators of B cell differentiation, such as Spi1, SpiB and Pax5, which are direct target genes of both TFAP4 and MYC. We therefore conclude that loss of TFAP4 leads to a block in differentiation during early B cell development, thereby accelerating c-MYC-driven lymphoma development.


INTRODUCTION
The oncogene c-MYC is abnormally highly expressed in~70% of human cancers [2]. Notably, c-MYC is commonly overexpressed in several haematological malignancies, such as Burkitt lymphoma (BL), a B cell malignancy driven by the t(8; 14) chromosomal translocation that subjugates the c-MYC gene under the control of the immunoglobulin heavy (IgH) chain gene enhancer Eµ [3]. The Eµ-MYC transgenic mouse serves as a pre-clinical model of BL and other malignancies driven by deregulated expression of c-MYC. These mice constitutively express human c-MYC under the control of the murine Eµ enhancer throughout B cell development leading to increased expansion of B cell progenitors that subsequently transform into lymphoma following the acquisition of cooperating oncogenic mutations [4][5][6].
Since the development of BL and other lymphoid malignancies requires additional genetic or epigenetic aberrations that cooperate with deregulated c-MYC expression, we previously set out to identify such cooperating mutations in an unbiased genome-wide functional genetic screen in vivo [1]. From this screen, we identified the transcription factor TFAP4 (also known as AP-4) as one of the top hits [1]. TFAP4 is a basic helix-loop-helix leucine zipper transcription factor reported to both activate or repress target gene expression upon homo-dimerisation [7]. Tfap4 expression itself is directly regulated by c-MYC. TFAP4 contributes to several c-MYC regulated cellular processes, including cell proliferation, cell cycle control and cellular senescence, by functional interaction with c-MYC including binding to the same gene promoter elements (reviewed by Wong et al. [8]). Of note, TFAP4 is critical for sustaining c-MYC-driven proliferation and maturation signals in B cells of the germinal centres following an infectious challenge through binding and regulating the same gene promoters [9]. Thus, TFAP4 is an important transcription factor acting downstream of and/or in parallel with c-MYC to regulate the proliferation and Ig class switching of mature B lymphoid cells.
TFAP4 has predominantly been identified as an oncogene that has been implicated in driving tumourigenesis by impacting the epithelial to mesenchymal transition, "stemness" and other cellular processes [8]. In certain human cancers high levels of TFAP4 expression correlate with poor prognostic outcomes [10,11]. However, these oncogenic properties of TFAP4 were found in solid cancers, such as breast cancer [12], colorectal carcinoma [13,14], gastric cancer [15], neuroblastoma [16,17] and certain others [18,19], and the role of TFAP4 in haematological malignancies has only been investigated in one study to date [20]. Interestingly, mutations in TFAP4 were identified in 9.7% of BL patient samples [21][22][23]. Conversely to solid cancers (see above), these were predominantly inactivating mutations, suggesting TFAP4 has tumour suppressive functions in this context. However, this type of analysis does not provide mechanistic insights into how defects in TFAP4 contribute to c-MYC-driven lymphomagenesis.
We employed Eµ-MYC/Cas9 doubly transgenic mice and a fetal liver derived HSPC transplantation approach to investigate the tumour suppressive role of TFAP4 during c-MYC-driven lymphoma development. We found that loss of TFAP4 led to malignant transformation at the pre-B cell stage, prior to surface Ig (sIg) expression. Gene expression analysis of pre-leukaemic pre-B cells revealed that several transcription factors important for B cell differentiation that, are also direct targets of TFAP4 and MYC, were abnormally reduced when TFAP4 was absent. This demonstrates that TFAP4 binds to and regulates key genes responsible for B cell differentiation and maturation. In Eµ-MYC transgenic B lymphoid cells the loss of TFAP4 dysregulates differentiation resulting in expansion of the rapidly proliferating pre-B cell pool that transforms into fully malignant c-MYC driven lymphoma.

MATERIALS AND METHODS Cell culture and lentivirus production
Recipes for the culture media for HEK293T cells and Eµ-MYC lymphoma cell lines (FMA medium) derived from primary tumours are listed in Supplementary Table S1 [24]. Cell lines were routinely tested for mycoplasma contamination. Some sgControl/Eµ-MYC/Cas9 lymphoma cell lines were previously used for experiments in [1]. Lentiviruses were generated using standard calcium phosphate precipitation methods as previously described [25]. Supernatants containing lentivirus particles were collected 48-72 h after transfection and passed through a 0.45 µM filter prior to infection of cells.

Experimental mice
The care and husbandry of experimental mice was conducted according to the guidelines outlined by The Walter and Eliza Hall Institute of Animal Ethics Committee. Eµ-MYC transgenic [4] and Cas9 transgenic mice (a gift from Prof K. Rajewsky, Max Delbrueck Centre, Berlin, Germany) were maintained on a C57BL/6-Ly5.2 background. C57BL/6-Ly5.1 and C57BL/6-Ly5.2 mice were obtained from the Walter and Eliza Hall Institute breeding facility (Kew, Victoria, Australia).

Haematopoietic reconstitution of lethally irradiated mice
Fetal liver cells (FLCs), a rich source of HSPCs, from Eµ-MYC/Cas9 double transgenic E13.5 embryos were harvested and frozen in 90% FCS and 10% (v/v) DMSO. Prior to transduction with sgRNA expression vectors, FLCs were thawed and cultured for 48 h in FLC medium (Supplementary  Table S1). Twelve-well non-tissue culture treated plates were coated with 32 µg/ml retronectin (WEHI) in PBS overnight at 4°C and then blocked with 2% bovine serum albumin solution (#A1595 Sigma-Aldrich) in PBS at 37°C for 30 min. Viral supernatant supplemented with 8 µg/ml polybrene was centrifuged onto the retronectin coated plates at 3500 rpm for 2 h at 32°C. Supernatant was removed and replaced with FLCs to be transduced for 24 h. These transduced cells were then collected, washed in PBS and injected intra-venously (i.v.) (random assignment of donor cells) into lethally irradiated (2 × 5.5 Gy, 4 h apart) 7-8 week-old C57BL/6-Ly5.1 recipient mice. Tumour-free survival was defined as the time from HSPC transplantation until the animal developed lymphoma and was deemed to have reached ethical endpoint by experienced animal research technicians who were blinded to the identity of the donor HSPCs used for transplantation of this mouse.

Analysis of pre-leukaemic pre-B cells
Reconstitution of lethally irradiated mice with FLCs was performed as described above, except that cells from one fetal liver were transduced and injected into two recipient mice, and recipient mice were harvested at 3 weeks post-transplantation. From these recipient mice, peripheral blood was collected by retro-orbital bleed into EDTA containing tubes and the spleen, thymus, lymph nodes (inguinal, brachial, axillary), and bone marrow (both femora and tibiae) were harvested and processed into single cell suspensions and counted as described above. Red blood cells were removed from peripheral blood and spleen cell suspensions by incubation in red cell removal buffer (Supplementary Table S1) for 5 min on ice and then washed twice. Cell suspensions were incubated in combinations of fluorochrome-conjugated antibodies against suitable surface markers (Supplementary Table S2). Staining with Propidium iodide (PI) was used for dead cell exclusion and cells were analysed in a Fortessa1 flow cytometer (Becton Dickinson).

Isolation of pre-leukaemic pre-B cells for RNA-sequence analysis
Pre-B cells were isolated from the bone marrow of recipient mice that had been transplanted 3 weeks earlier with sgTfap4/Eµ-MYC/Cas9 or sgControl/ Eµ-MYC/Cas9 FLCs. B cells were enriched from bone marrow of all long bones by staining with a cocktail of biotinylated antibodies against TER119 (Ly76), MAC-1 (M1/70), GR-1 (RB6-8C5) for 20 min on ice, washed, then incubated with MagniSort Streptavidin Negative Selection Beads (Thermo Fisher Scientific) according to the manufacturer's protocol to remove undesired erythroid and myeloid cells. The supernatant was transferred into a fresh tube, washed, and resuspended in 100 µl of a cocktail of fluorochromeconjugated antibodies against B220 (RA3-6B2), IgM (5.1), c-KIT (2B8) and 1 × 10 6 live (PI negative) pre-leukaemic pre-B cells (B220 + sIgM − c-KIT − ) were FACS sorted, centrifuged, and resuspended in QIAzol Lysis Reagent (Qiagen) and stored at −80°C. Total RNA was extracted using the QIAgen miRNeasy Mini Kit according to the manufacturer's instructions with optional oncolumn DNAase digestion. An input of 100 ng of total RNA was used to prepare mRNA libraries and indexed using the TruSeq RNA samples Prep Kit (illumina) according to the manufacturer's protocol. The samples were sequenced on an Illumina NextSeq using paired-end sequencing. RNAsequencing analysis are detailed in the Supplementary Material.

Statistical analysis
Data are presented as mean ± standard error of the mean (SEM) unless otherwise stated in figure legends. Statistical analysis was performed using GraphPad Prism software (v9.4.0); differences between two groups was determined using Student's t test; Welch's correction was applied if data did not fit a normal model; ANOVA test was used for comparing multiple groups. In vitro cell death curves were all log transformed and fitted to a non-linear regression model and the IC50 derived using GraphPad Prism software (v9.4.0). Sample sizes were determined to be able to observe statistically significant differences between control mice/cells and the genetically modified mice/cells, and experiments were replicated at least three times.
TFAP4 deficient Eµ-MYC lymphomas are not selected for defects in the TRP53 pathway Since~25% of lymphomas that spontaneously develop in Eµ-MYC transgenic mice show defects in the TRP53 pathway, we examined the sgTfap4/Eµ-MYC/Cas9 lymphomas, in which TFAP4 protein was absent, for abnormalities in the TRP53 pathway and compared them to the sgControl/Eµ-MYC/Cas9 lymphomas ( Fig. 2A). Interestingly, no TRP53 pathway alterations were detected in any of the sgTfap4/Eµ-MYC/Cas9 lymphomas tested by Western blotting for the levels of TRP53 and p19/ARF proteins (high levels of these proteins are an indicator for mutations in the Trp53 gene and/or TRP53 pathway defects) ( Fig. 2A, B) [28]. This contrasts with the sgControl/Eµ-MYC/Cas9 lymphoma cell lines, with~30% of those exhibiting TRP53 pathway aberrations using this assay. To assess functionality of the TRP53 pathway, we generated cell lines from the primary sgTfap4/Eµ-MYC/Cas9 and sgControl/Eµ-MYC/Cas9 lymphomas and demonstrated by flow cytometry that they are readily killed by treatment with nutlin-3A (a drug that activates TRP53 by blocking its major negative regulator MDM2 [29]) (Fig. 2C), and the DNA-damaging chemotherapeutic drug etoposide (Fig. 2D) that can also kill lymphoma cells through activation of TRP53 [30]. Collectively, these data reveal that loss of TFAP4 reduces the selection pressure for Eµ-MYC lymphomas to acquire defects in the TRP53 tumour suppressor pathway.
TFAP4 deficiency does not change reliance on pro-survival BCL-2 family members Avoiding cell death is one of the hallmarks of cancer [31], and this is often achieved by abnormally increased expression of pro-survival BCL-2 family members [32]. Eµ-MYC lymphoma cells are generally dependent on the pro-survival BCL-2 family member MCL-1 for their sustained survival [24,33]. We examined the responses of sgTfap4/Eµ-MYC/Cas9 and sgControl/Eµ-MYC/Cas9 lymphoma cell lines to the BH3 mimetic drugs ABT-199/Venetoclax [34] or S63845 [35] that inhibit BCL-2 or MCL-1, respectively. No differences in cell viability were observed between the sgTfap4 vs. sgControl/Eµ-MYC/Cas9 treated cells as measured at 24 h of treatment with these agents by flow cytometry (Supplementary Fig. 2a-c). These findings demonstrate that the absence of TFAP4 accelerates c-MYC-driven lymphoma development through mechanisms other than altering the dependency of these malignant cells on select pro-survival BCL-2 proteins.
TFAP4 impairs differentiation of Eµ-MYC transgenic B lymphoid cells at the pre-B stage Interestingly, we found that sgTfap4/Eµ-MYC/Cas9 lymphoma cell lines all represented neoplastic counterparts of surface Ig negative pre-B cells. In contrast, the sgControl as well as sgTrp53 Eµ-MYC/Cas9 lymphomas comprised a mixture of sIg negative pre-B lymphomas and sIg positive B cell lymphomas (Fig. 3A, B). This suggests that the absence of TFAP4 drives transformation at an early stage of B cell development. To better understand how TFAP4 deletion contributes to c-MYC-driven lymphoma development, a pre-leukaemic analysis was performed whereby recipient mice transplanted with either sgTfap4 or sgControl transduced Eµ-MYC/Cas9 HSPCs were harvested 3 weeks post-transplantation, a time point early during lymphomagenesis when their B lymphoid cells are not yet fully transformed. Bone marrow, spleen, thymus, lymph nodes and peripheral blood were analysed by flow cytometry to determine the proportions of the various B as well as T lymphocyte and myeloid cell subsets. No differences were observed in the total cellularity of the haematopoietic tissues between the sgTfap4/Eµ-MYC/Cas9 vs. the sgControl/Eµ-MYC/Cas9 groups (Supplementary Fig. 3a). Furthermore, the contribution of donor cells carrying both Cas9 (GFP positive) and the sgRNA (BFP positive) was comparable between the sgTfap4/Eµ-MYC/Cas9 vs. the sgControl/Eµ-MYC/Cas9 HSPCs transplanted cohorts across all haematopoietic tissues examined ( Supplementary Fig. 3b). However, these compartments were not completely composed of transduced donor HSPC derived cells. This can be explained because: (1)   donor cells. The latter is especially apparent for T lymphocytes and granulocytes: only a small percentage of these cell types were donor derived ( Supplementary Fig. 3c, d). Thus, to assess the impact of Tfap4 deletion in different cell types, only sgRNA/Cas9 doubly expressing (BFP + GFP + ) Eµ-MYC cells were examined.
Peripheral blood, bone marrow, spleen and lymph nodes showed significant differences in the B cell compartment between the sgTfap4/Eµ-MYC/Cas9 vs. the sgControl/Eµ-MYC/Cas9 HSPC transplanted cohorts. We detected higher proportions of surface Ig negative pro-B/pre-B cells (B220 + sIgM − sIgD − ) and a reduction in the proportions of mature B cells (B220 + sIg + ) in the sgTfap4/Eµ-MYC/Cas9 pre-leukaemic recipient mice compared to their sgControl/Eµ-MYC/Cas9 counterparts (Fig. 3C-G). In the peripheral blood and lymph nodes an increase in the proportion of sIgM + B cells was observed, likely because mature B cells circulate to these peripheral lymphoid tissues compared to the bone marrow and spleen, the sites of B cell development and maturation, respectively. This accumulation of pro-B/pre-B cells in the sgTfap4/Eµ-MYC/Cas9 preleukaemic recipients is consistent with the immuno-phenotyping of the malignant lymphomas arising in these mice (Fig. 3A, B).
TFAP4 deleted pre-leukaemic Eµ-MYC pre-B cells fail to upregulate transcriptional programmes required for B cell differentiation As TFAP4 is a transcriptional regulator, we next sought to understand how its loss might alter cell signalling pathways to accelerate c-MYC-driven lymphoma development. To this end we examined the B cell subsets in the bone marrow, the site of B cell development, by flow cytometry in the pre-leukaemic recipient mice. We observed a significant reduction in the percentages of donor derived mature B cells (B220 + sIgM + sIgD + ) and an increase in pro-B (B220 + sIgM − cKIT + ) and pre-B cells (B220 + sIgM − cKIT − ) in the sgTfap4/Eµ-MYC/Cas9 recipient mice compared to the sgControl/Eµ-MYC/Cas9 control recipient mice (Fig. 4A).
Our pre-leukaemic analysis and the immuno-phenotyping of the malignant Eµ-MYC lymphoma cells revealed that the absence of TFAP4 resulted in the accumulation of pre-B cells, indicating a block in B cell development as a possible cause of accelerated c-MYC-driven lymphomagenesis. Therefore, we assessed the expression of genes encoding master transcriptional regulators of B cell differentiation. Interestingly, sgTfap4/Eµ-MYC/Cas9 pre-leukaemic pre-B cells expressed lower levels of Pax5, the master regulator of B cell lineage specification (Fig. 5C). Furthermore, we observed a reduction in Spi1 (PU.1), SpiB, Irf8, Ikzf1 (Ikaros) and Ikzf3 (Aiolos), genes that orchestrate differentiation of common lymphoid progenitors into pro-B, pre-B and immature B cells (Fig. 5C) [40]. Interestingly, a previously reported TFAP4 ChIP-sequencing data set from pre-leukaemic Eµ-MYC pro-/pre-B cells [20] demonstrated direct binding of TFAP4 to the promoters of the Ikzf1, Ikzf3, Spi1, SpiB and Pax5 genes (Fig. 5D). Notably, these genes (data not available for Spi1) are also direct MYC target genes [41]. These findings demonstrate that the absence of TFAP4 impairs the differentiation of highly proliferative Eµ-MYC pre-leukaemic pre-B cells by reducing the levels of transcription factors that are critical for B cell differentiation (Fig. 5E).

DISCUSSION
Tfap4 is a direct c-MYC target gene that was reported to contribute to certain c-MYC regulated cellular processes, including apoptosis, cell proliferation and cellular senescence [42]. Induction of Tfap4 by c-MYC to coordinate these processes has been implicated in neoplastic transformation of several solid cancers [8]. This contrasts our findings, where not over-expression but rather the absence of TFAP4, through CRISPR/Cas9 mediated deletion, accelerated c-MYC-driven lymphomagenesis. In the context of c-MYC-driven lymphoma development, loss of TFAP4 does not alter apoptosis or cell proliferation, as the genes regulating these processes were not differentially expressed in pre-leukaemic pre-B cells lacking TFAP4. However, we observed aberrantly reduced expression of transcription factors that are critical for B cell differentiation, including Ikzf1, Ikzf3, Spi1, SpiB and Pax5. This indicates that TFAP4 deficiency accelerates lymphoma development by impairing B cell differentiation, representing an emerging hallmark of cancer [31]. Of note, Tfap4 deletion on its own either in the whole organism or specifically in B lymphoid cells does not drive tumorigenesis. [9,20]. Preliminary experiments deleting TFAP4 in HSPCs and transplanting them into lethally irradiated animals similarly did not cause any malignant growth (our data not shown).
Recently, Tonc et al. [20] showed that TFAP4 is frequently mutated in human mature B cell malignancies. Furthermore, they showed, that patients with paediatric B progenitor cell acute lymphoblastic leukaemia (B-ALL) showing TFAP4-low/MYC-high expression had significantly poorer overall survival compared to those showing TFAP4-high/MYC-high expression. Additionally, this study revealed that loss of Tfap4, either a single allele or both alleles, accelerated c-MYC-driven lymphoma development in mice. This work was conducted by employing both whole body Tfap4 knockout as well as conditional Tfap4 knockout mouse models crossed with Eµ-MYC transgenic mice as well as with other mouse models of c-MYC driven lymphoid malignancies. Concordant with our findings, all tumours Tonc et al. found in their Tfap4 −/− Eµ-MYC mice were pro-B/pre-B cell lymphomas. However, their preleukaemic analysis using Tfap4 +/− Eµ-MYC mice showed no differences in the numbers of cells within the different B cell subsets [20]. The difference between their findings and our observations is likely due to the different model systems employed. In our case, the use of CRISPR/Cas9 results in complete deletion of Tfap4, evident by loss of TFAP4 protein ( Fig. 2A), whereas the pre-leukaemic cells Tonc et al. examined retained one allele of Tfap4, albeit some of these cells selected for loss of the second allele, highlighting that there is potent selection for loss of Tfap4 in c-MYC-driven lymphoma development. Despite not observing differences in the proportions of B cell subsets at the different stages of differentiation in their pre-leukaemic mice, Tonc et al. [20] concluded that TFAP4 restricts c-MYC regulated B cell stemness because they found an upregulation of Erg, a direct target gene of TFAP4, that regulates haematopoietic stemness. While we also observed increased levels of Erg in the sgTfap4/Eµ-MYC/Cas9 pre-leukaemic pre-B cells in our RNA-seq analysis (Fig. 5C), we noted a reduction in several master regulators of B cell differentiation. We observed abnormally reduced expression of Spi1 (PU.1), SpiB, Ikzf1 (Ikaros) and Ikzf3 (Aiolos) in sgTfap4/Eµ-MYC/Cas9 pre-leukaemic pre-B cells; these are direct target genes of both TFAP4 and MYC [41]. The contribution of these genes to normal B cell development and the impact of defects in their expression have been well characterised (reviewed by Pang et al. [40]). Interestingly, the deletion of Spi1 (PU.1) or SpiB impairs B cell differentiation, and mice lacking these transcriptional regulators develop B-ALL [43,44]. Furthermore, loss of Ikzf11 (Ikaros) or Ikzf3 (Aiolos) is associated with B-ALL development in both mice and humans [40,45,46]. Pax5 deletion has been shown to prevent B cell differentiation beyond the pro-B cell stage [40] and its knockdown drives the development of B-ALL due to a differentiation block [47]. We therefore propose that TFAP4 is required for differentiation of c-MYC over-expressing pre-B cells through transcriptional regulation of Spi1, SpiB, Ikzf1, Ikzf3 and Pax5. The reduced activation of these genes caused by the absence of TFAP4, in combination with aberrant c-MYC expression, prevents normal B cell differentiation causing an increase in the pool of highly proliferative pro-B/pre-B cells facilitating the acquisition of oncogenic lesions that cooperate with deregulated c-MYC expression in lymphomagenesis (Fig. 5E). Thus, restoring TFAP4 expression in c-MYC driven blood cancers, might ameliorate disease progression, not by killing the tumour cells, but by Fig. 5 Genes regulating B cell differentiation are down-regulated in TFAP4 deleted pre-leukaemic Eµ-MYC pre-B cells. Lethally irradiated recipient mice were transplanted with Eµ-MYC/Cas9 FLCs that had been transduced with a vector containing either a sgTfap4 (n = 8) or a sgControl (n = 6), and the pre-leukaemic pre-B cells from these recipient mice were analysed at 3 weeks post-transplantation by RNA-sequencing. Relative expression (RPKM-reads per kilobase million) of selected gene transcripts regulating apoptosis (A), cell cycling and proliferation (B), or master transcription factors and coordinators of B cell differentiation as well as Erg (C). Statistical significance *adj. p < 0.05, FDR < 0.05. D Spi1, SpiB, Ikzf1, Ikzf3 and Pax5 genomic loci coverage plots of anti-TFAP4 and anti-H3K27ac (a marker of accessible chromatin) binding in pre-leukaemic Eµ-MYC pro/pre-B cells. Y-axis represents counts per million (CPM), gene isoforms pictured, thick bar indicates exons, orange box highlights binding. Data accessed from GSE133514 [20]. E Proposed mechanism: in wild-type mice normal B cell development occurs, whereby pre-B cells differentiate into immature B cells expressing surface IgM. In Eµ-MYC transgenic mice, c-MYC is abnormally overexpressed in the B cell lineage causing excess proliferation of pro-B/pre-B cells and a partial block in their differentiation, thereby producing an abnormally expanded pool of pre-leukaemic pre-B cells and some sIg + B cells. Some of these cells will acquire oncogenic mutations that can collaborate with c-MYC over-expression in neoplastic transformation and consequently give rise to pre-B or B cell lymphoma. The absence of TFAP4 in the Eµ-MYC setting results in an even larger pool of pre-leukaemic pre-B cells arising due to the further restriction of differentiation by downregulation of transcription factors that are critical for B cell differentiation. This even larger pool of highly proliferative pre-leukaemic pre-B cells is thus more likely to acquire additional mutations that drive transformation into malignant surface Ig − pre-B cell lymphoma. inducing normal differentiation of the self-renewing pre-B lymphoma cell pool into less proliferative immature/mature B cells, albeit only if these cells are dependent on sustained absence of TFAP4 for lymphoma maintenance and not only for lymphoma development.

DATA AVAILABILITY
RNA-sequencing data have been deposited on NCBI-GEP with the accession number GSE225684.